Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease
Identifieur interne : 001302 ( Main/Exploration ); précédent : 001301; suivant : 001303Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease
Auteurs : Anne Marthe Meppelink [Pays-Bas] ; Rickard Nyman [Suède] ; Teus Van Laar [Pays-Bas] ; Martje Drent [Pays-Bas] ; Ted Prins [Pays-Bas] ; Klaus Leonhard Leenders [Pays-Bas]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-02-01.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Carbidopa (administration & dosage), Carbidopa (therapeutic use), Drug Combinations, Duodenum, Female, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson's disease, Patient Satisfaction, Quality of Life, Severity of Illness Index, Treatment Outcome, T‐port, duodopa.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug therapy : Parkinson Disease.
- Administration, Cutaneous, Adult, Aged, Drug Combinations, Duodenum, Female, Humans, Male, Middle Aged, Patient Satisfaction, Quality of Life, Severity of Illness Index, Treatment Outcome.
Abstract
Motor fluctuations in Parkinson's disease (PD) can be reduced by intraduodenal infusion of levodopa‐carbidopa (Duodopa®) via percutaneous endoscopic gastrojejunostomy (PEG). We applied the transcutaneous soft‐tissue anchored titanium port (T‐port) in 15 PD patients with motor fluctuations; 7 Duodopa‐naive (non‐PEG), and 8 previously receiving Duodopa (former‐PEG). Motor scores (UPDRS‐III) and quality of life (QOL, PDQ‐8) were assessed at baseline and 6 month follow‐up. Six patients had local irritation shortly after implantation, persisting in one patient at 6 month follow‐up, which led to explantation. After having finished the protocol, four T‐ports were explanted in total. UPDRS‐III and PDQ‐8 scores improved moderately in the non‐PEG patients, but remained similar in the former‐PEG users. Two former‐PEG users developed polyneuropathy. No obstructions, retractions, or leakages occurred. Technical and hygienic properties of the T‐port were preferred by most patients. The T‐port seems to be suitable for most PD patients qualifying for Duodopa therapy, although local infection may lead to explantation during longer‐term follow‐up. © 2010 Movement Disorder Society.
Url:
DOI: 10.1002/mds.23408
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B59
- to stream Istex, to step Curation: 000B59
- to stream Istex, to step Checkpoint: 000034
- to stream PubMed, to step Corpus: 001494
- to stream PubMed, to step Curation: 001494
- to stream PubMed, to step Checkpoint: 001018
- to stream Ncbi, to step Merge: 002F23
- to stream Ncbi, to step Curation: 002F23
- to stream Ncbi, to step Checkpoint: 002F23
- to stream Main, to step Merge: 001355
- to stream Main, to step Curation: 001302
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease</title><author><name sortKey="Meppelink, Anne Marthe" sort="Meppelink, Anne Marthe" uniqKey="Meppelink A" first="Anne Marthe" last="Meppelink">Anne Marthe Meppelink</name></author><author><name sortKey="Nyman, Rickard" sort="Nyman, Rickard" uniqKey="Nyman R" first="Rickard" last="Nyman">Rickard Nyman</name></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></author><author><name sortKey="Drent, Martje" sort="Drent, Martje" uniqKey="Drent M" first="Martje" last="Drent">Martje Drent</name></author><author><name sortKey="Prins, Ted" sort="Prins, Ted" uniqKey="Prins T" first="Ted" last="Prins">Ted Prins</name></author><author><name sortKey="Leenders, Klaus Leonhard" sort="Leenders, Klaus Leonhard" uniqKey="Leenders K" first="Klaus Leonhard" last="Leenders">Klaus Leonhard Leenders</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A52EF0F3FCCD74A527348C5B0797F5EF444D8108</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23408</idno><idno type="url">https://api.istex.fr/document/A52EF0F3FCCD74A527348C5B0797F5EF444D8108/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B59</idno><idno type="wicri:Area/Istex/Curation">000B59</idno><idno type="wicri:Area/Istex/Checkpoint">000034</idno><idno type="wicri:doubleKey">0885-3185:2011:Meppelink A:transcutaneous:port:for</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:20960486</idno><idno type="wicri:Area/PubMed/Corpus">001494</idno><idno type="wicri:Area/PubMed/Curation">001494</idno><idno type="wicri:Area/PubMed/Checkpoint">001018</idno><idno type="wicri:Area/Ncbi/Merge">002F23</idno><idno type="wicri:Area/Ncbi/Curation">002F23</idno><idno type="wicri:Area/Ncbi/Checkpoint">002F23</idno><idno type="wicri:Area/Main/Merge">001355</idno><idno type="wicri:Area/Main/Curation">001302</idno><idno type="wicri:Area/Main/Exploration">001302</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease</title><author><name sortKey="Meppelink, Anne Marthe" sort="Meppelink, Anne Marthe" uniqKey="Meppelink A" first="Anne Marthe" last="Meppelink">Anne Marthe Meppelink</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Nyman, Rickard" sort="Nyman, Rickard" uniqKey="Nyman R" first="Rickard" last="Nyman">Rickard Nyman</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Diagnostic Radiology, University Hospital Uppsala, Uppsala</wicri:regionArea><wicri:noRegion>Uppsala</wicri:noRegion></affiliation></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Drent, Martje" sort="Drent, Martje" uniqKey="Drent M" first="Martje" last="Drent">Martje Drent</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Prins, Ted" sort="Prins, Ted" uniqKey="Prins T" first="Ted" last="Prins">Ted Prins</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Radiology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Leenders, Klaus Leonhard" sort="Leenders, Klaus Leonhard" uniqKey="Leenders K" first="Klaus Leonhard" last="Leenders">Klaus Leonhard Leenders</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-02-01">2011-02-01</date><biblScope unit="vol">26</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="331">331</biblScope><biblScope unit="page" to="334">334</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A52EF0F3FCCD74A527348C5B0797F5EF444D8108</idno><idno type="DOI">10.1002/mds.23408</idno><idno type="ArticleID">MDS23408</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (therapeutic use)</term><term>Drug Combinations</term><term>Duodenum</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Patient Satisfaction</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term><term>T‐port</term><term>duodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Aged</term><term>Drug Combinations</term><term>Duodenum</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Satisfaction</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Motor fluctuations in Parkinson's disease (PD) can be reduced by intraduodenal infusion of levodopa‐carbidopa (Duodopa®) via percutaneous endoscopic gastrojejunostomy (PEG). We applied the transcutaneous soft‐tissue anchored titanium port (T‐port) in 15 PD patients with motor fluctuations; 7 Duodopa‐naive (non‐PEG), and 8 previously receiving Duodopa (former‐PEG). Motor scores (UPDRS‐III) and quality of life (QOL, PDQ‐8) were assessed at baseline and 6 month follow‐up. Six patients had local irritation shortly after implantation, persisting in one patient at 6 month follow‐up, which led to explantation. After having finished the protocol, four T‐ports were explanted in total. UPDRS‐III and PDQ‐8 scores improved moderately in the non‐PEG patients, but remained similar in the former‐PEG users. Two former‐PEG users developed polyneuropathy. No obstructions, retractions, or leakages occurred. Technical and hygienic properties of the T‐port were preferred by most patients. The T‐port seems to be suitable for most PD patients qualifying for Duodopa therapy, although local infection may lead to explantation during longer‐term follow‐up. © 2010 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li><li>Suède</li></country><region><li>Groningue (province)</li></region><settlement><li>Groningue</li></settlement></list><tree><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Meppelink, Anne Marthe" sort="Meppelink, Anne Marthe" uniqKey="Meppelink A" first="Anne Marthe" last="Meppelink">Anne Marthe Meppelink</name></region><name sortKey="Drent, Martje" sort="Drent, Martje" uniqKey="Drent M" first="Martje" last="Drent">Martje Drent</name><name sortKey="Leenders, Klaus Leonhard" sort="Leenders, Klaus Leonhard" uniqKey="Leenders K" first="Klaus Leonhard" last="Leenders">Klaus Leonhard Leenders</name><name sortKey="Prins, Ted" sort="Prins, Ted" uniqKey="Prins T" first="Ted" last="Prins">Ted Prins</name><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></country><country name="Suède"><noRegion><name sortKey="Nyman, Rickard" sort="Nyman, Rickard" uniqKey="Nyman R" first="Rickard" last="Nyman">Rickard Nyman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A52EF0F3FCCD74A527348C5B0797F5EF444D8108
|texte= Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |